NCT05527509 Risk and Resiliency Factors in the RCMP: A Prospective Investigation
| NCT ID | NCT05527509 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Regina |
| Condition | Posttraumatic Stress Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 960 participants |
| Start Date | 2019-04-22 |
| Primary Completion | 2024-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 960 participants in total. It began in 2019-04-22 with a primary completion date of 2024-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Royal Canadian Mounted Police (RCMP), like all public safety personnel (PSP), are frequently exposed to potentially psychologically traumatic events that contribute to posttraumatic stress injuries (PTSI). Addressing PTSI is impeded by the limited available research. The RCMP are working to build evidence-based solutions to PTSI and other mental health challenges facing their members, which by extension will help all PSP, as part of the Canadian Government Federal Framework on Posttraumatic Stress Disorder. A key element is the "Longitudinal Study of Operational Stress Injuries / Étude longitudinale sur les traumatismes liés au stress opérationnel", a study which has been renamed "Risk and Resiliency Factors in the RCMP: A Prospective Investigation", and is referred to as the "RCMP Study" for short. The RCMP Study has been detailed online (www.rcmpstudy.ca) and in a recently published peer-reviewed protocol paper, "The Royal Canadian Mounted Police (RCMP) Study: protocol for a prospective investigation of mental health risk and resilience factors" (https://doi.org/10.24095/hpcdp.42.8.02). The RCMP Study, part of the concerted efforts by the RCMP to reduce PTSI by improving access to evidence-based assessments, treatments, and training as well as participant recruitment and RCMP Study developments to date. The RCMP Study has been designed to (1) develop, deploy and assess the impact of a system for ongoing annual, monthly and daily evidence-based assessments; (2) evaluate associations between demographic variables and PTSI; (3) longitudinally assess individual differences associated with PTSI; (4) augment the RCMP Cadet Training Program with skills to proactively mitigate PTSI; and (5) assess the impact of the augmented training condition (ATC) versus the standard training condition (STC). Participants in the STC (n = 480) and ATC (n = 480) are assessed before and after training and annually for 5 years on their deployment date; they also complete brief monthly and daily surveys. The RCMP Study results are expected to benefit the mental health of all participants, RCMP and PSP by reducing PTSI among all who serve.
Eligibility Criteria
Inclusion Criteria: * Cadets starting the RCMP Cadet Training Program Exclusion Criteria: * Anyone other than cadets starting the RCMP Cadet Training Program
Contact & Investigator
R. Nicholas Carleton, PhD
PRINCIPAL INVESTIGATOR
University of Regina
Frequently Asked Questions
Who can join the NCT05527509 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 57 Years, studying Posttraumatic Stress Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05527509 currently recruiting?
Yes, NCT05527509 is actively recruiting participants. Contact the research team at nick.carleton@uregina.ca for enrollment information.
Where is the NCT05527509 trial being conducted?
This trial is being conducted at Regina, Canada.
Who is sponsoring the NCT05527509 clinical trial?
NCT05527509 is sponsored by University of Regina. The principal investigator is R. Nicholas Carleton, PhD at University of Regina. The trial plans to enroll 960 participants.